# High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

> **NCT06812871** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 46 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** furmonertinib

## Key facts

- **NCT ID:** NCT06812871
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-01
- **Primary completion:** 2025-10-20
- **Final completion:** 2026-03-30
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06812871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06812871, "High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06812871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*